Compare Packaging Corporation of America (PKG) vs Summit Therapeutics Inc (SMMT) Price & Performance

Packaging Corp of America (PKG) trades at $228.43, down 1.99% on the day, with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $8.99B revenue and 8.04% net margin, though recent earnings show mixed performance with Q1 2026 beating estimates but Q3/Q4 2025 missing. A 20% dividend increase to $6.00 annually reflects management confidence. Analyst consensus is mixed with 34.62% buy ratings and a $256.14 price target suggesting 12% upside potential.

PKG presents a balanced investment case with attractive dividend yield and analyst upside, but faces earnings volatility and margin pressure. The upcoming Q2 2026 earnings report on July 22 will be crucial for confirming growth trajectory. Key risks include integration challenges from the Greif acquisition and ongoing cost pressures affecting profitability.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.